Skip to main content

Advertisement

SpringerLink
Log in

Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren’s syndrome

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

B cell activating factor (BAFF), also called the B lymphocyte stimulator, has been known to show increased expression in primary Sjögren’s syndrome (pSS) which could explain increased B cell activation characteristic of this disease. Belimumab, a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator (Blys), has been reported to be efficacious in systemic lupus erythematosus (SLE) through its B cell-mediated action. Randomized controlled trials of belimumab in a selected target population of pSS patients are further warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gorgoulis V, Giatromanolaki A, Iliopoulos A, Kanavaros P, Aninos D, Ioakeimidis D, Kontomerkos T, Karameris A (1993) EGF and EGF-r immunoexpression in Sjögren’s syndrome secondary to rheumatoid arthritis. Correlation with EBV expression? Clin Exp Rheumatol 11(6):623–627

    CAS  PubMed  Google Scholar 

  2. Azuma N, Katada Y, Kitano S, Sekiguchi M, Kitano M, Nishioka A, Hashimoto N, Matsui K, Iwasaki T, Sano H (2014) Correlation between salivary epidermal growth factor levels and refractory intraoral manifestations in patients with Sjögren’s syndrome. Mod Rheumatol 24(4):626–632

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Internal Medicine, Lincoln Medical And Mental Health Center, New York, NY, USA

    Sabeeda Kadavath

  2. Rheumatology, Westchester Medical Center, New York, NY, USA

    Slavica Bobic

  3. Division of Rheumatology, New York Methodist Hospital, 506 Sixth Street, Brooklyn, NY, 11215, USA

    Petros Efthimiou

  4. Department of Medicine, Weill Cornell Medical College, New York, NY, 10021, USA

    Petros Efthimiou

Authors
  1. Sabeeda Kadavath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Slavica Bobic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petros Efthimiou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petros Efthimiou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kadavath, S., Bobic, S. & Efthimiou, P. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren’s syndrome. Clin Rheumatol 34, 1651–1652 (2015). https://doi.org/10.1007/s10067-015-2872-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2872-7

Keywords

Search

Navigation